Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in three upcoming conferences:

  • Canaccord Genuity 39th Annual Growth Conference

    Date:
    Thursday, August 8, 2019

    Location: Boston, MA
  • BTIG Biotechnology Conference 2019

    Date:
    Monday, August 12, 2019

    Location: New York, NY
  • 2019 Wedbush PacGrow Healthcare Conference

    Date:
    Tuesday, August 13, 2019

    Location: New York, NY

    Presentation Time: 10:20 a.m. ET

A live webcast of 2019 Wedbush PacGrow Healthcare Conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!